INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia, and it has an extremely variable course. 1, 2 Other than allogeneic stem-cell transplantation, which is considered an appropriate therapy for selected patients with poor prognosis only, there is no curative treatment. 1, 3 However, over the past five decades, the management of CLL apart from stem-cell transplantation has evolved considerably, resulting in high and durable response rates. 4, 5 The purine analog fludarabine and its combinations have markedly improved treatment success demonstrating higher response rates and longer progression-free survival (PFS) in younger patients with CLL. [6] [7] [8] [9] [10] [11] More recent trials evaluated the impact of chemoimmunotherapy in patients with CLL showing that the addition of the anti-CD20 monoclonal antibody rituximab to fludarabine and cyclophosphamide improved PFS and overall survival (OS).
10, [12] [13] [14] However, the findings were associated with an increased toxicity: 76% of the patients experienced at least one grade 3 or 4 event; hematologic toxicity grade 3 or 4 occurred in 56% of the patients.
14 Bendamustine has structural similarities to both alkylating agents and purine analogs and has shown considerable activity as a single agent for lymphoid malignancies, including CLL. [15] [16] [17] [18] [19] Encouraging clinical results have been obtained by using bendamustine in combination with rituximab in relapsed and/or refractory CLL in many elderly and high-risk patients with advanced disease. 20 In light of these promising clinical data, we initiated this phase II trial to evaluate the safety and efficacy of bendamustine and rituximab combination treatment in previously untreated patients with symptomatic CLL regardless of age and fitness.
PATIENTS AND METHODS

Study Design and Objective
This prospective, multicenter, nonrandomized, phase II study was approved by the competent institutional review board and was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines. All patients provided written informed consent. The primary end point was the overall response rate (ORR). Secondary end points included toxicity, quality and duration of response, event-free survival (EFS), minimal residual disease (MRD) levels, and ORR in biologically defined risk groups.
Patients and Treatment Schedule
Patients included in the trial had to be diagnosed with CLL in need of treatment according to the National Cancer Institute (NCI) guidelines. Eligible patients were at least 18 years of age, had a WHO performance status of 0 to 2, a life expectancy of at least 12 weeks, and adequate renal (creatinine clearance Ͼ 30 mL/min) and liver function (total bilirubin, aminotransferases Յ 2 ϫ the institutional upper limit of normal). All patients were scheduled to receive 90 mg/m 2 bendamustine on days 1 and 2 combined with 375 mg/m 2 rituximab on day 0 for the first course and 500 mg/m 2 on day 1 for all subsequent courses, based on previously published data for fludarabine, cyclophosphamide, and rituximab.
10, 21 Treatment was administered every 28 days for up to six courses, depending on response and toxicity.
Assessments
Patients underwent baseline assessment before first treatment. During therapy, assessment for adverse events and myelosuppression were performed weekly. After three courses of treatment, an interim response assessment was performed. Patients who had achieved at least stable disease with acceptable toxicity continued to receive study treatment for three additional courses. Restaging after completion of therapy was performed 1 month Ϯ 7 days after the start of the last course of therapy and had to be reconfirmed 2 months later. Subsequently, patients completed follow-up examinations every 3 months for the ensuing 36 months (Fig 1) .
Criteria for Response and Toxicity
Response was determined according to the NCI Working Group 1996 Criteria for CLL, including bone marrow examination and radiographic confirmation of complete response (CR). 22 Responses and disease progression were assessed by the study investigators and verified by a central investigator independent medical review. The response achieved after termination of therapy had to be maintained for at least 2 months. Radiographic imaging was performed at the discretion of the treating physician at screening and during interim staging and follow-up. Treatment toxicity was reported by the investigators according to NCI Common Toxicity Criteria (CTC) version 3.0.
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Biologic Prognostic Markers
Analysis of genomic aberrations by interphase fluorescent in situ hybridization, immunoglobulin heavy variable chain (IGHV) mutational status by sequencing, MRD by four-color flow cytometry of peripheral blood and bone marrow, and flow cytometric assessment of CD38 and ZAP-70 expression were performed in the central reference laboratories of the German CLL Study Group.
24,25
Statistical Methods
The sample size estimation was performed according to the Simon twostage optimal design with type I error ϭ 0.05 to determine the efficacy of a regimen that was not of interest (response rate Ͻ 70%) and a type II error ϭ 0.10, suggesting the rejection of an active regimen (response rate Ͼ 90%). 12, 26 The primary end point of ORR was calculated on the intent-to-treat (ITT) population defined by all patients who received at least one dose of study medication. Secondary end points were the response rate in biologically defined risk groups, MRD response rate, and the duration of response, defined as the time period between the first documentation of response and the initial documentation of progressive disease or death as a result of any cause. An additional secondary end point was EFS defined as the date of first treatment with bendamustine and rituximab (BR) to the date of progressive disease, the beginning of new treatment for any hematologic malignancy, or death as a result of any cause. Median EFS and duration of response were estimated by the Kaplan-Meier method and were performed for the ITT population.
RESULTS
Patient Characteristics
Between March 2007 and September 2008, 117 patients were enrolled onto the trial at 40 centers in Germany. All 117 patients received at least one dose of treatment and constitute the ITT population for basic characteristics, safety, and efficacy analysis. The median age was 64.0 years (range, 34.0 to 78.0 years). Thirty patients (25.6%) were age 70 years or older and 46.2% of patients were at Binet stage C at study entry. Forty-one patients (35.0%) had a creatinine clearance Յ 70 mL/min (Table 1) .
A deletion of chromosome 17p13 (del(17p)) was detected in 7.3% of the patients, del(11q) in 19.1%, and unmutated IGHV in 61.8%. The study cohort was characterized by the following high-risk features: 80% of the patients were characterized by high levels of serum thymidine kinase (s-TK Ͼ10 U/L; median, 26.0 U/L; range, 2.0 to 600.0 U/L), 45.9% of patients presented with high levels of serum ␤ 2 -microglobulin (Ͼ 3.5 mg/L; median, 3.4 mg/L; range, 0.2 to 10.0 mg/L), and 15.7% of patients were positive for ZAP-70 expression (Table 1) .
Treatment
A total of 599 treatment courses were administered (median number per patient, 6.0): 86 patients (73.5%) received the full six courses of therapy, three patients received five courses, seven patients received four courses, six received three courses, seven received two courses, and eight received one course. Therefore, 102 patients (87.2%) received at least three courses. Eighty-five patients (72.6%) received infectious prophylaxis (Appendix, online only) before treatment. Granulocyte colony-stimulating factor was administered to 25 patients (21.4%) for a median duration of 5 days. In 73 patients (62.4%), treatment was delayed between 1 and 28 days. Regarding the dose-intensity, 58 patients (49.6%) received the full dose-intensity of BR; the median dose-intensity of rituximab was nearly 100%. Dose reductions of either of the two drugs by more than 10% of the planned dose were used for 59 patients (50.4%), mostly because of treatmentrelated hematologic toxicity. Thirty patients (25.6%) had a dose reduction of rituximab alone, 47 (40.2%) of bendamustine alone, and 16 patients (13.7%) had dose reductions of both rituximab and bendamustine. Treatment was discontinued early (during the first or second course of therapy) in 15 patients (12.8%) because of withdrawal of consent (n ϭ 1), toxicity (n ϭ 8), allergic reaction (n ϭ 1), protocol violation (n ϭ 2), progressive disease (n ϭ 2), or other reason (n ϭ 1).
Safety
After a median follow-up time of 27 months, 11 deaths occurred: cause of death in six patients was unrelated to treatment in disease progression; among the six patients, three were diagnosed with Richter's transformation. Treatment-related mortality was 3.4%: one patient died after the second course of therapy as a result of liver failure following attempted suicide with doxylamine. Two patients died during their second course of therapy and one during the fifth course of therapy from infections that were related to therapy.
Seventy-five patients (64.1%) experienced at least one adverse event of CTC grade 3 or 4 during treatment or up to 2 months (Table 2) . On the basis of the number of treatment courses, severe neutropenia, thrombocytopenia, and anemia were observed in 6.0%, 5.7%, and 4.5% of all applied treatment courses, respectively (Table 2) .
Two patients entered the study with an active hemolysis; both cases were stabilized under study treatment. Infection was the most common nonhematologic toxicity. Infections (12 grade 3; three grade 4), mainly febrile neutropenias and pneumonias, occurred in nine patients (7.7%). The numbers of other nonhematologic toxicities are listed in Table 2 . Of note, the incidence of nonhematologic toxicity was higher in patients older than age 70 years compared with patients age Յ 70 years (65.4% v 33.0%; P ϭ .004).
Also of note, the incidence of severe leukopenia, anemia, and nonhematologic toxicity was higher in patients with a creatinine clearance Յ 70 mL/min compared with patients with normal renal function (41.5% v 23.7% [P ϭ .057], 37.7% v 14.5% [P ϭ .033], and 51.2% v 34.2% [P ϭ .08], respectively). Patients with an impaired creatinine clearance did not require more dose reductions (P ϭ .56) but did experience more infections than patients with a creatinine clearance greater than 70 mL/min (29.3% v 15.8% [P ϭ .097]).
Treatment Efficacy
On the basis of the ITT population, the ORR was 88.0% (95% CI, 80.7% to 100.0%; n ϭ 103), with a CR rate of 23.1% (n ϭ 27), 1.7% nodular partial responses (n ϭ 2), and a partial response rate of 63.2% (n ϭ 74). Stable disease was observed in 9.4% (n ϭ 11), and none of the patients had progressive disease. In three patients (2.6%), no response assessment was performed as a result of death before interim staging (n ϭ 2) and diagnosis of mantle-cell lymphoma during the 
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first course of therapy (n ϭ 1). Excluding these patients from analysis, ORR and CR rates were 90.4% and 23.7%, respectively. After a median observation time of 27.0 months, the median EFS was 33.9 months (95% CI, 31.9 to 35.9 months). As for OS, 106 patients (90.5%) were still alive. Median EFS was reached at 35.5 months for patients with Binet stage C and at 32.4 months for patients with Binet stage B. For patients with Binet stage A, median EFS has not been reached. Among the 103 responders, the median duration of response was 31.4 months (95% CI, 29.0 to 33.8 months ; Fig 2) .
At the time-point of final staging, 26 (57.8%) of 45 patients had peripheral blood MRD levels below 10 Ϫ4 . Seven (29.2%) of 24 patients achieved MRD negativity in bone marrow. Patients were stratified by MRD into low-(Ͻ 10 Ϫ4 ), intermediate-(Ն 10 Ϫ4 to Ͻ 10 Ϫ2 ), and high-level (Ͼ 10 Ϫ2 ) cohorts. Low-level MRD in blood and/or bone marrow was associated with prolonged EFS (P Ͻ .001; Table 3 ). In peripheral blood, median EFS was 32.4 months and 11.8 months for intermediate-and high-level MRD groups, respectively, whereas median EFS has not been reached for patients with NOTE. N/R indicates not reached at time of analysis. Abbreviations: CR, complete response; EFS, event-free survival; IGHV, immunoglobulin heavy chain V; MRD, minimal residual disease; ORR, overall response rate; PD, progressive disease; PFS, progression-free survival; PR/nPR, nodular partial response; s-␤ 2 m, serum ␤ 2 -microglobulin; SD, stable disease; s-TK, serum thymidine kinase.
‫ء‬
Number of patients without response assessment. †Not including 17p deletion. ‡Not including 17p or 11q deletion.
low-level MRD (Fig 2) . Median OS for patients with high-level MRD was 23.2 months and has not been reached for patients with intermediate-and low-level MRD.
Treatment Efficacy in Prognostic Subgroups
Pretreatment characteristics and clinical and biologic parameters were evaluated for correlations with ORR. ORR was significantly associated with higher cumulative doses of bendamustine and rituximab (bendamustine, P Ͻ .001; rituximab, P Ͻ .001), lower age (Յ 65 years; P ϭ .026), higher level of hemoglobin (Ͼ 10.0 g/dL; P ϭ .003), and lower level of s-TK at study entry (Յ 10 U/L; P ϭ .023). In terms of the prognostic factors CD38 and ZAP-70, a significant level was not achieved when using the established cutoff levels for CD38 and ZAP-70.
Differences in response to treatment were observed among the genetic subgroups (P ϭ .001): 18 patients (90.0%) with del(11q) achieved a remission, and eight patients (40%) achieved a CR. Accordingly, 18 patients (94.7%) with trisomy 12 responded to treatment with a CR rate of 21.1%. In the high-risk group with del(17p), three patients (37.5%) achieved a partial response. Kaplan-Meier analysis showed significant differences for EFS (P Ͻ .001), as listed in Table 3 and shown in Figure 3 . Fifty-nine patients (89.4%) with unmutated IGHV status were responsive to treatment with a CR rate of 27.3%. Significant differences in EFS were also found for patients with a high level of s-TK (P ϭ .009; Table 3 ). Of the patients who had an impaired creatinine clearance of Յ 70 mL/min, 89.7% achieved a response (Table 3) .
DISCUSSION
The addition of rituximab to chemotherapeutic regimens has significantly improved the impact of treatment for both treatment-naive patients and those with relapsed CLL. [10] [11] [12] 14 To the best of our knowledge, this phase II trial is the first trial prospectively assessing safety and efficacy of bendamustine in combination with rituximab in patients with previously untreated CLL.
Compared with a recently published trial 14 evaluating efficacy of fludarabine, cyclophosphamide, and rituximab (FCR) in a fairly young and physically fit patient population (median age, 61 years), the study population in our trial included a significant proportion of patients (accounting for more than a quarter of the entire study population) who were age 70 years or older. Moreover, 46.2% of the patients presented with Binet stage C at study entry. In addition, 35% of patients had impaired renal function and were therefore not eligible for treatment with FCR.
In light of the patient population in our trial, the ORR of 88.0% (95% CI, 80.7% to 100.0%), including a 23.7% CR rate with a median EFS of 33.9 months, is similar to the results achieved by a study that used chemoimmunotherapy with FCR 14 and reported an ORR of 90% with a CR rate of 44% and a median PFS of 51.8 months. Compared with the German CLL Study Group (GCLLSG) CLL8 trial exploring the FCR regimen in first-line treatment of CLL, this trial included older patients (median age, 64 v 61 years) with more advanced disease (46.2% v 31% of patients at Binet stage C). The inferior CR rate might be partially explained by the incidence of a high proportion of patients with a clinical CR (n ϭ 28) that did not fulfill the strict CR criteria according to NCI criteria because of missing bone marrow biopsy and missing radiographic examination (n ϭ 14), missing bone marrow biopsy (n ϭ 11), or incomplete clinical response because of toxicity (n ϭ 3). Despite the fact that results of bone marrow biopsies are missing for many patients, it would be inappropriate to add the clinical complete responses to the CR rate. However, the MRD results described earlier also reported a higher number of patients who were MRD free by flow cytometry in peripheral blood.
14,27 Interestingly, the MRD levels achieved in this trial predicted an EFS and PFS similar to that recently reported for treatment with FCR or FC: 11. Compared with trials that used FCR in first-line CLL, the observed adverse effects of the BR regimen compare favorably, although the study population in our trial displayed more poor-risk factors. Although severe neutropenia of grade 3 and higher was noticed in only 19.7% of patients and 6.0% of courses treated with BR, this rate was reported to be between 34% per patient and 24% per course in the trials evaluating FCR and 13% per course in a trial using FCR-Lite.
10,14, 28 The incidence of both thrombocytopenia (grade 3 to 4, 22.2%) and anemia (grade 3 to 4, 19.7%) appearstobehighercomparedwiththereportednumbersintheFCRtrial because different versions of the NCI-CTC were used for grading hematologic toxicities (version 3.0 for this trial, version 2.0 for CLL8). When applying CTC version 2.0, grade 3 to 4 thrombocytopenia occurred in 11.5% of the patients, and grade 3 anemia occurred in 4.3% of the patients. The reported low rate of severe infections in 7.7% of patients receiving BR treatment also compares favorably to the rate in patients receiving FCR, with a reported infection rate of 25%.
14 Importantly, other nonhematologic adverse effects were rare. In particular, no neurologic adverse effects or skin reactions were observed in our trial, although they have occasionally been reported in other trials that use bendamustine. 29, 30 In conclusion, we describe a representative population of patients with CLL (including patients with advanced disease and renal function impairment) who received BR treatment for their previously untreated disease. Except for patients with del(17p) who did not respond to the treatment regimen as the other genetic subgroups, the combination of bendamustine and rituximab offers an effective and safe treatment for patients with treatment-naive CLL. To evaluate the use of BR in elderly patients with CLL or in those with CLL who do not qualify for treatment, further studies with well-defined patient populations with an assessment of a comorbidity score need to be performed. On the basis of the promising results obtained in this phase II trial, we initiated a phase III trial comparing the BR regimen with standard first-line therapy (FCR) for physically fit patients with previously untreated CLL to study the question of whether therapy with BR is not inferior to therapy with FCR.
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